Can you summarize the key dimensions of the LEADER trial evaluating the effect of liraglutide on CV outcomes, including its design, physiologic rationale, data collection, and clinical objectives?

Can you summarize the key dimensions of the LEADER trial evaluating the effect of liraglutide on CV outcomes, including its design, physiologic rationale, data collection, and clinical objectives?

Can you summarize the key dimensions of the LEADER trial evaluating the effect of liraglutide on CV outcomes, including its design, physiologic rationale, data collection, and clinical objectives?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Itamar Raz, MD

Itamar Raz, MD

Professor of Internal Medicine
Head of the Diabetes Unit
Hadassah University Hospital
Jerusalem, Israel